NASDAQ | VICL: 2.13  -0.05
investors
Investors

News Releases

DateSubject
December 13, 2010 Vical's Vaxfectin® Demonstrates Potential as "Universal" Adjuvant
November 18, 2010 Vical to Explore Vaxfectin® Partnering Opportunities at International Veterinary Vaccine Conference
November 17, 2010 Vical Enters Into Agreement With Japanese Partner for Veterinary Pandemic Influenza Vaccine
November 9, 2010 Vical Reports Third Quarter 2010 Financial Results and Updates on Key Programs and Confirms Planned Webcast of Analyst and Investor Day Event
November 2, 2010 Vical Announces News Release Schedule for Third Quarter 2010 Financial Results and Plans to Host Analyst and Investor Day in New York
October 29, 2010 Vical Names Igor Bilinsky Senior Vice President, Corporate Development
October 27, 2010 Vical to Update Herpes Simplex Vaccine Program at Keystone Conference
October 14, 2010 Vical to Present at NewsMakers Conference
October 7, 2010 Vical to Manufacture DNA Vaccines for Advanced Development by HIV Consortium
October 5, 2010 Vical Updates TransVax™ CMV Vaccine Program at World Vaccine Congress
September 24, 2010 Vical Incorporated Prices Public Offering of Common Stock
September 23, 2010 Vical Incorporated Announces Proposed Public Offering of Common Stock
September 13, 2010 Vical's TransVax™ CMV Vaccine Achieves Statistical Significance on Key Clinical Endpoints in Phase 2 Trial
September 9, 2010 Vical To Present TransVax™ CMV Vaccine Phase 2 Results at ICAAC and Host Concurrent Conference Call and Webcast
September 8, 2010 Vical to Present at Stifel Nicolaus Healthcare Conference
August 4, 2010 Vical to Present at Canaccord Genuity Growth Conference
August 3, 2010 Vical Reports Second Quarter 2010 Financial Results and Progress in Key Programs
July 27, 2010 Vical Announces News Release and Conference Call Schedule for Second Quarter 2010 Financial Results
July 26, 2010 Vical's Herpes Simplex Vaccines Protect Against Lethal Challenge and Demonstrate Significant Therapeutic Benefit in Animal Models
June 16, 2010 Vical's Allovectin-7® Phase 3 Trial Receives Positive Review From Safety Monitoring Board
June 7, 2010 Vical to Present at Two Upcoming Investor Conferences
June 1, 2010 Vical to Present at Three Upcoming Investor Conferences
May 25, 2010 Vical Collaborators Receive Grant to Pursue Novel CMV Vaccine Strategies
May 24, 2010 Vical to Close NASDAQ Stock Market
May 12, 2010 Allovectin-7® Achieves Median Survival of Nearly 19 Months in Phase 2 Melanoma Trial
May 11, 2010 Vical to Present at Rodman & Renshaw Global Healthcare Conference
May 6, 2010 Vical Reports First Quarter 2010 Financial Results and Progress in Key Programs
May 5, 2010 Vical Begins Phase 1 Trial of DNA Vaccine Against H1N1 Pandemic Influenza
April 30, 2010 Vical CEO Selected as Panelist at BIO and PGH Conferences
April 29, 2010 Vical Announces News Release and Conference Call Schedule for First Quarter 2010 Financial Results
April 27, 2010 Vical Reports Encouraging Updates From U.S. Military Malaria Vaccine Programs
April 22, 2010 Vical Presents Encouraging Preliminary Data From Final 12-month Follow-up in TransVax(TM) CMV Vaccine Phase 2 Transplant Recipient Trial
March 22, 2010 Vical Secures Funding to Proceed With Phase 1 Trial of H1N1 Pandemic Influenza Vaccine
March 1, 2010 Vical to Present at Upcoming Investor Conferences
February 24, 2010 Publication of Vical's H5N1 Results Paves the Way for H1N1 Clinical Trial
February 11, 2010 Vical Reports 2009 Financial Results and Progress in Key Development Programs
February 4, 2010 Vical Announces News Release and Conference Call Schedule for 2009 Financial Results
January 28, 2010 Vical Completes Enrollment in Allovectin-7® Phase 3 Trial for Metastatic Melanoma
January 26, 2010 Vical Updates Vaccine Development Programs for CMV and Pandemic Influenza
January 14, 2010 Vical Names Richard T. Kenney, M.D., Vice President of Clinical Development
January 12, 2010 Vical Licensee AnGes MG Reaches Agreement With FDA For Phase 3 Trial of Collategene™ Angiogenesis Product
January 11, 2010 Vical Announces Licensee's Approval of ONCEPT™ Therapeutic Melanoma Vaccine for Dogs
January 8, 2010 Vical Secures $25 Million Issuer Managed Equity Facility With Azimuth Opportunity, Ltd.
January 7, 2010 Mechanism of Action for Vical's Vaxfectin® Adjuvant Expands Potential Applications

AnGes Ebola Antibody Therapy

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.